Global Immune mediated Necrotizing Myopathy Treatment Industry

Global Immune-mediated Necrotizing Myopathy Treatment Industry Research & Trends Analysis Report

Global Immune mediated Necrotizing Myopathy Treatment Industry

Global Immune-mediated Necrotizing Myopathy Treatment Industry Research & Trends Analysis Report


Insights into the Immune-mediated Necrotizing Myopathy Treatment Market include supply chain optimization, Immune-mediated Necrotizing Myopathy Treatment challenges, and growth forecasts segmented by region and service type.

Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!

According to Market IntelliX Research, the global market for Immune-mediated Necrotizing Myopathy Treatment should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

China Immune-mediated Necrotizing Myopathy Treatment market should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

The United States Immune-mediated Necrotizing Myopathy Treatment market should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

In terms of type, Steroids segment holds a share about % in 2023 and will reach % in 2030; while in terms of application, Hospital has a share approximately % in 2023 and will grow at a CAGR % during 2024 and 2030.

The global key manufacturers of Immune-mediated Necrotizing Myopathy Treatment include GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries and Novartis AG, etc. In 2023, the global top five players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive study of the global market for Immune-mediated Necrotizing Myopathy Treatment. Report Highlights:

(1) Global Immune-mediated Necrotizing Myopathy Treatment market size (value),history data from 2019-2024 and forecast data from 2024 to 2030.

(2) Global Immune-mediated Necrotizing Myopathy Treatment market competitive situation, revenue and market share, from 2018 to 2022.

(3) China Immune-mediated Necrotizing Myopathy Treatment market competitive situation, revenue and market share, from 2018 to 2022.

(4) Global Immune-mediated Necrotizing Myopathy Treatment segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.

(5) Global Immune-mediated Necrotizing Myopathy Treatment segment by type and by application and regional segment by type and by application.

(6) Immune-mediated Necrotizing Myopathy Treatment industry supply chain, upstream, midstream and downstream analysis.

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa

Market segment by type, covers

Steroids

Immunosuppressant

Others

Market segment by application, can be divided into

Hospital

Clinic

Others

Market segment by players, this report covers

GlaxoSmithKline plc

Dr. Reddy's Laboratories

Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)

Hetero Drugs Limited

AbbVie Inc.

Teva Pharmaceutical Industries

Novartis AG

1 Market Overview

1.1 Product Overview and Scope of Immune-mediated Necrotizing Myopathy Treatment

1.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Size and Forecast

1.3 China Immune-mediated Necrotizing Myopathy Treatment Market Size and Forecast

1.4 China Market Percentage in Global

1.4.1 By Revenue, China Immune-mediated Necrotizing Myopathy Treatment Share in Global Market, 2019-2030

1.4.2 Immune-mediated Necrotizing Myopathy Treatment Market Size: China VS Global, 2019-2030

1.5 Immune-mediated Necrotizing Myopathy Treatment Market Dynamics

1.5.1 Immune-mediated Necrotizing Myopathy Treatment Market Drivers

1.5.2 Immune-mediated Necrotizing Myopathy Treatment Market Restraints

1.5.3 Immune-mediated Necrotizing Myopathy Treatment Industry Trends

1.5.4 Immune-mediated Necrotizing Myopathy Treatment Industry Policy

2 Global Competitive Situation by Company

2.1 Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Company (2019-2024)

2.2 Global Immune-mediated Necrotizing Myopathy Treatment Participants, Market Position (Tier 1, Tier 2 and Tier 3)

2.3 Global Immune-mediated Necrotizing Myopathy Treatment Concentration Ratio

2.4 Global Immune-mediated Necrotizing Myopathy Treatment Mergers & Acquisitions, Expansion Plans

2.5 Global Immune-mediated Necrotizing Myopathy Treatment Manufacturers Product Type

3 China Competitive Situation by Company

3.1 China Immune-mediated Necrotizing Myopathy Treatment Revenue by Company (2019-2024)

3.2 China Immune-mediated Necrotizing Myopathy Treatment Immune-mediated Necrotizing Myopathy Treatment Participants, Market Position (Tier 1, Tier 2 and Tier 3)

3.3 China Immune-mediated Necrotizing Myopathy Treatment, Revenue Percentage of Local Players VS Foreign Manufacturers (2019-2024)

4 Industry Chain Analysis

4.1 Immune-mediated Necrotizing Myopathy Treatment Industry Chain

4.2 Immune-mediated Necrotizing Myopathy Treatment Upstream Analysis

4.3 Immune-mediated Necrotizing Myopathy Treatment Midstream Analysis

4.4 Immune-mediated Necrotizing Myopathy Treatment Downstream Analysis

5 Sights by Type

5.1 Immune-mediated Necrotizing Myopathy Treatment Classification

5.1.1 Steroids

5.1.2 Immunosuppressant

5.1.3 Others

5.2 By Type, Global Immune-mediated Necrotizing Myopathy Treatment Market Size & CAGR, 2019 VS 2024 VS 2030

5.3 By Type, Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2030

6 Sights by Application

6.1 Immune-mediated Necrotizing Myopathy Treatment Segment by Application

6.1.1 Hospital

6.1.2 Clinic

6.1.3 Others

6.2 By Application, Global Immune-mediated Necrotizing Myopathy Treatment Market Size & CAGR, 2019 VS 2024 VS 2030

6.3 By Application, Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2030

7 Sales Sights by Region

7.1 By Region, Global Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019 VS 2024 VS 2030

7.2 By Region, Global Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030

7.3 North America

7.3.1 North America Immune-mediated Necrotizing Myopathy Treatment Market Size & Forecasts, 2019-2030

7.3.2 By Country, North America Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share

7.4 Europe

7.4.1 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size & Forecasts, 2019-2030

7.4.2 By Country, Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share

7.5 Asia Pacific

7.5.1 Asia Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size & Forecasts, 2019-2030

7.5.2 By Country/Region, Asia Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share

7.6 South America

7.6.1 South America Immune-mediated Necrotizing Myopathy Treatment Market Size & Forecasts, 2019-2030

7.6.2 By Country, South America Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share

7.7 Middle East & Africa

8 Sights by Country Level

8.1 By Country, Global Immune-mediated Necrotizing Myopathy Treatment Market Size & CAGR，2019 VS 2024 VS 2030

8.2 By Country, Global Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030

8.3 U.S.

8.3.1 U.S. Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030

8.3.2 By Company, U.S. Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2024

8.3.3 By Type, U.S. Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.3.4 By Application, U.S. Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.4 Europe

8.4.1 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030

8.4.2 By Company, Europe Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2024

8.4.3 By Type, Europe Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.4.4 By Application, Europe Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.5 China

8.5.1 China Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030

8.5.2 By Company, China Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2024

8.5.3 By Type, China Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.5.4 By Application, China Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.6 Japan

8.6.1 Japan Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030

8.6.2 By Company, Japan Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2024

8.6.3 By Type, Japan Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.6.4 By Application, Japan Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.7 South Korea

8.7.1 South Korea Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030

8.7.2 By Company, South Korea Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2024

8.7.3 By Type, South Korea Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.7.4 By Application, South Korea Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.8 Southeast Asia

8.8.1 Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030

8.8.2 By Company, Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2024

8.8.3 By Type, Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.8.4 By Application, Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.9 India

8.9.1 India Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030

8.9.2 By Company, India Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2024

8.9.3 By Type, India Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.9.4 By Application, India Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.10 Middle East & Asia

8.10.1 Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030

8.10.2 By Company, Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2024

8.10.3 By Type, Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

8.10.4 By Application, Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2023 VS 2030

9 Global Manufacturers Profile

9.1 GlaxoSmithKline plc

9.1.1 GlaxoSmithKline plc Company Information, Head Office, Market Area and Industry Position

9.1.2 GlaxoSmithKline plc Company Profile and Main Business

9.1.3 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application

9.1.4 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2019-2024

9.1.5 GlaxoSmithKline plc Recent Developments

9.2 Dr. Reddy's Laboratories

9.2.1 Dr. Reddy's Laboratories Company Information, Head Office, Market Area and Industry Position

9.2.2 Dr. Reddy's Laboratories Company Profile and Main Business

9.2.3 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application

9.2.4 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2019-2024

9.2.5 Dr. Reddy's Laboratories Recent Developments

9.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)

9.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Information, Head Office, Market Area and Industry Position

9.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Profile and Main Business

9.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application

9.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2019-2024

9.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Developments

9.4 Hetero Drugs Limited

9.4.1 Hetero Drugs Limited Company Information, Head Office, Market Area and Industry Position

9.4.2 Hetero Drugs Limited Company Profile and Main Business

9.4.3 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application

9.4.4 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2019-2024

9.4.5 Hetero Drugs Limited Recent Developments

9.5 AbbVie Inc.

9.5.1 AbbVie Inc. Company Information, Head Office, Market Area and Industry Position

9.5.2 AbbVie Inc. Company Profile and Main Business

9.5.3 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application

9.5.4 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2019-2024

9.5.5 AbbVie Inc. Recent Developments

9.6 Teva Pharmaceutical Industries

9.6.1 Teva Pharmaceutical Industries Company Information, Head Office, Market Area and Industry Position

9.6.2 Teva Pharmaceutical Industries Company Profile and Main Business

9.6.3 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application

9.6.4 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2019-2024

9.6.5 Teva Pharmaceutical Industries Recent Developments

9.7 Novartis AG

9.7.1 Novartis AG Company Information, Head Office, Market Area and Industry Position

9.7.2 Novartis AG Company Profile and Main Business

9.7.3 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application

9.7.4 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2019-2024

9.7.5 Novartis AG Recent Developments

10 Conclusion

11 Appendix

11.1 Research Methodology

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Market Estimation Model

11.4 Disclaimer

Tables & Figures:
Show more
Research Methodology:
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Immune-mediated Necrotizing Myopathy Treatment Market Size Estimation

To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.

Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.

Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.

We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.

Data Source

Secondary Sources

This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.

These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.

Market Size
  • Segmental value
  • Geographic Penetration
  • Product Adoption Rate for Different market
  • Journals, Websites, and Press Releases
  • Annual Reports and SEC Filings
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Market Intellix Data Repository
Market Position of Top Company
  • Product Financials
  • Geographic value Mix
  • Total Company value
  • Business/Segmental value Mix
Qualitative Analysis
  • Influence Factors
  • Market Potential
  • Market Risks and Opportunities
  • Industry Trends
  • Geographical Features
  • Government Policies
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Annual Reports
  • Industry Associations
  • Market Intellix Data Repository

Primary Sources

As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.

On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.

These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.

Key Data Information from Primary Sources

Primary Sources Parameters Key Data
Market Segments(by Application, by Type)
  • Value by Type
  • Status and Forecast
  • Value by Application
  • Value by Regions, Status and Forecast (2025-2031)
  • Value Market Share by Type
  • Value Growth Rate by Type
  • Value by Application
  • Percentage and Growth Rate by Application
  • Value Growth Rate and Market Share by Regions
  • Market Size Status and Forecast (2025-2031)
Total Market
  • Overall Size, Status and Forecast
  • Market Size Status and Forecast (2025-2031)
Frequently asked questions(FAQ's):
How are players chosen for the research coverage of the Immune-mediated Necrotizing Myopathy Treatment Market study?
MI used a variety of industry standards such as NAICS, ICB, TRIC, and others to identify functional players in the industry, which they then shortlist and validate in an iterative process to finalize the most relevant players.
What years are taken into account in the Immune-mediated Necrotizing Myopathy Treatment Market study?
The Immune-mediated Necrotizing Myopathy Treatment Market study evaluates the year spans as follows: Historical year: 2019 to 2024; Base year: 2024; Forecast period**: 2025 to 2030 [** unless otherwise stated]
In the current situation, what value does the Immune-mediated Necrotizing Myopathy Treatment Market have?
The value of the Immune-mediated Necrotizing Myopathy Treatment Market is estimated to be USD XXX million.
What are the top priorities for the growth of the Immune-mediated Necrotizing Myopathy Treatment Market?
In this highly competitive and rapidly evolving Immune-mediated Necrotizing Myopathy Treatment Industry, top strategic priorities such as innovation, diversification, and M&A would remain consistent.